The shareholders of Tübingen-based CureVac AG have elected two new Supervisory Board members. This was announced by the biotech company at the beginning of the week. As a result, the Supervisory Board has expanded from six to eight members – in line with the motto the more the better. “We are very pleased to welcome Tim Wright and Craig Tooman as new board members,” said Ingmar Hoerr, chairman and co-founder of the company.
Investors: Dietmar Hopp & Bill Gates
Former Novartis and Pfizer manager Timothy Wright is currently a full-time “General Partner” at TIME BioVentures in San Diego. Craig Tooman has been CEO of US veterinary specialist Aratana Therapeutics since January, where he previously served as Chief Financial Officer. Supervisory Board Chairman Hoerr praised Wright’s “comprehensive expertise in drug development” and Tooman’s “know-how in financial and operational areas of the pharmaceutical and biotechnology industry”. CureVac hopes to gain valuable expertise from the two new members of the Supervisory Board in order to achieve the company’s goal of producing its own medicines by programming its genetic material. Investors include SAP founder Dietmar Hopp and the Bill & Melinda Gates Foundation.